Two conjunctival leaking blebs were excisioned to assess by histological methods the cellular effect after corneal cross-linking treatment. Sections were stained with hematoxylin-eosin and immunohistochemistry with the Ki67 antibody. The proliferating marker Ki67 was detected only in both treated pieces with a very signifi cant increase in epithelial proliferating cells in one case but not in the other. Further studies are necessary to continue understanding the response to treatment of the ischemic blebs with CXL and ribofl avin.
Introduction
Corneal collagen crosslinking (CXL), using ultraviolet-A (UVA) radiation and ribofl avin, it is a non-invasive treatment of progressive keratoconus. As the procedure has shown a positive effect on the biomechanical of the cornea it could be a real alternative for late-onset bleb leakage in certain cases. Recent published studies [1, 2] , show encouraging results with this simple and non-invasive technique. Although in both series only one eye had a signifi cant intraocular pressure (IOP) increase in the fi rst set and two in the second, almost in all treated eyes the seidel test were normalized, which would support the postulate that CXL reinforces residual collagen bonding. However, in most of the eyes a slight IOP increase was observed and it is hardly attributable to the treatment because these eyes have a self-resolving tendency with a self-limiting seidel phenomena with fl uctuating visual acuity.
Materials and Methods
To assess the cellular effect in the conjunctival leaking cystic blebs after corneal cross-linking treatment we have excisioned two cystic conjunctival blebs treated with MMC (0.02 mgr/mL for 2 minutes) of two eyes with a previous history of glaucoma surgery. The subjects gave their informed consent for the study. After excision, one piece of both ischemic tissues was treated with CXL and Ribofl avin ex-vivo, keeping the other piece as a control. One Ribofl avin drop (0.1% without dextran, Mediocross©M) was applied every 2 min for 20 minutes, followed by UVA irradiation 9 mW/cm2 -10 minutes (CCL VarioSystem, Ophtec®). Samples were then fi xed in formalin and embedded in paraffi n, and sequential sections were stained with hematoxylin-eosin and immunohistochemistry with the Ki67 antibody.
Results
The hematoxylin-eosin (H&E) study did not show any signifi cant difference between the treated piece with CXL and ribofl avin and the untreated piece ( Figure 1 ). The proliferating marker Ki67 was detected only in both treated pieces with a very signifi cant increase in epithelial proliferating cells in one case but not in the other (Figure 2 ).
Discussion
Our fi ndings can probably indicate proliferative cell variability and these results should be interpreted with caution because they are only two cases, but our observations point on Wollensak´s [3] , study of rabbits that fi nds the same distribution pattern in all treatment groups and controls. It could be as Wang [2] , stated, that in the fi rst case, the fi broblasts remainder that are present in the 75% of the leaking MMC treated blebs [4] , and the growth-arrested cells, existing around the margin of the ischemic blebs were able to stimulate a fi brovascular repair, being responsible for the observed epithelial growth and makes the difference between those which will respond to treatment and those that will not. In addition, some indemnity of the basal cell layer underlying the Ki67 positive cells [3] , could help the epithelial repair. We also have to consider that the epithelium wound healing process after the treatment with CXL, UVA and Ribofl avin could explain the response and add this restorative process to the hypothetical formation of covalent bonds among collagen fi bres. We agree with Choy [1] , that it could be a real alternative between conservative treatment and surgical procedures but further studies are necessary to continue understanding the response to treatment of the ischemic blebs with CXL and ribofl avin which could be a simple alternative, economical, non-invasive and potentially repeatable.
